New shot could soothe severe eczema itch
NCT ID NCT07445919
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests an experimental drug called SM17, given as a shot under the skin, for adults with moderate-to-severe eczema (atopic dermatitis). The goal is to see if it safely reduces skin redness, swelling, and itching. About 200 participants will receive either SM17 or a placebo, and researchers will track skin improvement over 16 weeks.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
Peking University People's Hospital
RECRUITINGBeijing, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new injection calm severe eczema when creams fall short?
- Can a new biologic calm severe eczema?
- Can a daily probiotic soothe colicky babies and calm eczema?
- Can a new injection match an existing eczema treatment?
- Can Real-World data unlock better skin disease care?
- Can a meditation app soothe teen eczema?